To further understand bortezomib's effect on enhancing immune mechanisms and reducing tumor burden by modulating immunostimulatory cytokines, we investigated a therapeutic setup where we adoptively transferred Cln4 CD8+T cells specific to the HA518-526 epitope (Vβ8.1 clonotype) into 4T1HA tumor-bearing mice. The gene discussed is CD8A; the disease is neoplasm.